Scholarlink

<p><i>Staphylococcus aureus</i> is a major contributor to biofilm-associated infections, which complicate the treatment of chronic conditions like osteomyelitis and prosthetic infections. This study aimed to evaluate the activity of delafloxacin, a novel fluoroquinolone, against biofilm-forming <i>S. aureus</i> strains, including methicillin-resistant and methicillin-sensitive isolates. Delafloxacin’s efficacy was compared with traditional antibiotics (vancomycin, linezolid, doxycycline, sulfamethoxazole/trimethoprim, and rifampicin) using minimal inhibitory concentration assays, including testing at different pH levels to simulate acidic biofilm conditions. Synergistic interactions were assessed using the checkerboard method. Biofilm eradication was tested through minimal biofilm eradication concentration assays, biomass quantification, and cell viability. The results showed that all isolates were susceptible to vancomycin and linezolid, with varying levels of resistance to other antibiotics. Delafloxacin demonstrated potent activity, with MIC reductions observed in acidic conditions. Biofilm eradication tests revealed limited success in eradicating biofilms at breakpoint concentrations. However, rifampicin in combination with delafloxacin significantly reduced biofilm biomass in some isolates. No significant changes in cell viability were noted across treatments. This study highlights delafloxacin’s potential against biofilm-associated infections, particularly in acidic environments. Despite the challenges in biofilm eradication, delafloxacin combined with rifampicin shows promise for improved treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating the efficacy of delafloxacin and combination therapy against Staphylococcus aureus Biofilms: insights into activity in acidic environments

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Ana Paula de Andrade,
  • Paula Hansen Suss,
  • Jaqueline Pilon de Meneses,
  • Gabriel Burato Ortis,
  • Felipe Francisco Tuon

摘要

Staphylococcus aureus is a major contributor to biofilm-associated infections, which complicate the treatment of chronic conditions like osteomyelitis and prosthetic infections. This study aimed to evaluate the activity of delafloxacin, a novel fluoroquinolone, against biofilm-forming S. aureus strains, including methicillin-resistant and methicillin-sensitive isolates. Delafloxacin’s efficacy was compared with traditional antibiotics (vancomycin, linezolid, doxycycline, sulfamethoxazole/trimethoprim, and rifampicin) using minimal inhibitory concentration assays, including testing at different pH levels to simulate acidic biofilm conditions. Synergistic interactions were assessed using the checkerboard method. Biofilm eradication was tested through minimal biofilm eradication concentration assays, biomass quantification, and cell viability. The results showed that all isolates were susceptible to vancomycin and linezolid, with varying levels of resistance to other antibiotics. Delafloxacin demonstrated potent activity, with MIC reductions observed in acidic conditions. Biofilm eradication tests revealed limited success in eradicating biofilms at breakpoint concentrations. However, rifampicin in combination with delafloxacin significantly reduced biofilm biomass in some isolates. No significant changes in cell viability were noted across treatments. This study highlights delafloxacin’s potential against biofilm-associated infections, particularly in acidic environments. Despite the challenges in biofilm eradication, delafloxacin combined with rifampicin shows promise for improved treatment strategies.